<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172404</url>
  </required_header>
  <id_info>
    <org_study_id>205.220</org_study_id>
    <nct_id>NCT02172404</nct_id>
  </id_info>
  <brief_title>HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Single-blind Two-centre Trial to Compare Administration Technique, Learning Retention of the Administration Technique and Ease of Use of the HandiHaler® With Those of the Pressurised Metered Dose Inhaler (MDI) in Patients With COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the
      learning retention of the administration technique for the HandiHaler® vs. MDI and to compare
      the ease of use for HandiHaler® vs. MDI
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance score based on the checklist for each device</measure>
    <time_frame>Day 0 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of errors on all scoring attempts per device use</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of scoring attempts per device use</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incorrect answers to the &quot;knowledge of use&quot; questionnaire per device use</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Set of patient responses to the &quot;ease of use&quot; questionnaire</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients responses to the questionnaire</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>HandiHaler® vs. MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDI vs. HandiHaler®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo capsule administered via the HandiHaler®</intervention_name>
    <arm_group_label>HandiHaler® vs. MDI</arm_group_label>
    <arm_group_label>MDI vs. HandiHaler®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ipratropium metered dose inhaler (MDI)</intervention_name>
    <arm_group_label>HandiHaler® vs. MDI</arm_group_label>
    <arm_group_label>MDI vs. HandiHaler®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic obstructive pulmonary disease and must meet the following
             spirometric criteria:

               -  Historical data (not older than 6 months) of stable airway obstruction with an
                  forced expiratory volume at one second (FEV1) ≤ 80% of predicted normal and FEV1
                  ≤ 70% of forced vital capacity (FVC)

          -  Male or female patients with 40 years of age or older

          -  Smokers or ex-smokers with a smoking history of more than 10 pack-years

          -  Currently using a prescription bronchodilator (such as Atrovent®, Berodual®,
             Combivent®, salbutamol, etc.) administered at least once daily

          -  Able to read and understand written instructions, understand verbal instructions and
             fill out written questionnaires regarding the devices

          -  Able to give informed consent prior to participation in the trial, including
             discontinuation of any medications, sign an approved consent form, and be willing and
             able to complete all trial procedures

        Exclusion Criteria:

          -  Any acute or chronic illness which could interfere with the conduct of completion of
             the trial, including but not limited to cardiovascular, renal, neurologic, liver,
             immunologic, or endocrine dysfunction if clinically significant

          -  Current or recent (past 2 years) history of drug or alcohol abuse

          -  Participation in any other clinical trial or use if any investigational drug within
             the last 30 days prior to visit 1

          -  Experience with the HandiHaler®

          -  Discontinued use of regularly prescribed use of MDI within the last 12 months.

          -  Treatment with any oral or injectable β-blockers within the recent 4 weeks prior to
             visit 1

          -  Treatment with oral β-adrenergics within the recent 4 weeks prior to visit 1

          -  Current or recent (last 6 weeks prior to visit 1) respiratory illness including, but
             not limited to upper or lower respiratory tract infections or asthma

          -  Patients who are in a pulmonary rehabilitation program or who had completed a
             pulmonary rehabilitation program in the 6 weeks prior to visit 1

          -  Patients with known hypersensitivity to ipratropium bromide, lactose or any other
             components of the inhalation capsule delivery system

          -  Patients with known sensitivity to inhaled β-agonists

          -  Patient using oral corticosteroid medication at unstable doses (i.e., less than 6
             weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of
             prednisolone per day or 20 mg every other day

          -  Pregnant or nursing women or women of childbearing potential not using medically
             approved means of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

